Senores Pharmaceuticals Limited — PPTs, 23-07-2025: Investor Presentation

**1. Financial Highlights:**

Senores Pharma reported robust Q1 FY26 consolidated results: Income soared 72% YoY to Rs. 138.0 Cr, EBITDA jumped 60% to Rs. 34.2 Cr, and PAT surged 95% to Rs. 21.2 Cr. Margins were strong: Gross 55.5%, EBITDA 24.8%, PAT 15.4%. Operating cash flow was positive at Rs. 11 Cr.

**2. Strategic Initiatives & Growth Drivers:**

Strategic priorities include expanding Regulated Markets' ANDA portfolio & CDMO/CMO, and enhancing Emerging Markets' profitability. Plans involve significant API capacity expansion and increasing Havix subsidiary stake to 78%.

**3. Business Developments:**

Q1 saw 2 ANDA product launches & 4 approvals. CDMO/CMO added 5 products. Branded Generics revenue surged 117% QoQ (+357% YoY), targeting pan-India reach by FY26. Emerging Markets also gained 23 new product registrations.

**4. Market Position & Competitive Advantage:**

A key differentiator is their USFDA & DEA approved facility, enabling government contract and controlled substance supply in the US. Strong R&D and a specialized product portfolio across diverse markets underscore their competitive edge.

**5. Investor Implications:**

Robust Q1 growth and a strategic focus on high-margin segments signal positive potential. Investors should monitor the efficient deployment of substantial unutilized IPO funds for CapEx and inorganic growth.